ICU sedation, delirium & recovery
Immunotherapy on ICU : a narrative review
Authors' conclusion
Despite significant advances in the development of targeted immunotherapy, the mechanism of action for the resultant toxicities remains poorly understood and limits the development of predictive models, diagnostic biomarkers and highly effective treatment options.
Study context
- Population
- Patients in critical care receiving chimeric antigen receptor T-cell therapy or immune checkpoint inhibitors for malignant disease
- Outcome
- Toxicities of CAR T-cell therapy and immune checkpoint inhibitors
Methodological detailsSearches of electronic databases; basic science, clinical trials, cohort studies, systematic reviews, meta-analyses and guidelines eligible
- Searches of electronic databases; basic science, clinical trials, cohort studies, systematic reviews, meta-analyses and guidelines eligible
Main finding
As reported in the abstract
- Pathophysiology of toxicities incompletely understood; targeted drug therapies successfully implemented for toxicities such as cytokine release syndrome
- Corticosteroids remain an important component of pharmacological management
- Diagnosis of toxicities largely clinical; high index of suspicion for infective complications
- Management with the patient's primary oncologist
Original publication
Immunotherapy on ICU : a narrative review. Anaesthesia. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →